Details
| Original language | English |
|---|---|
| Article number | 2794 |
| Journal | Cells |
| Volume | 11 |
| Issue number | 18 |
| Publication status | Published - 7 Sept 2022 |
Abstract
Recent studies have shown that circulating levels of irisin are prognostic factors in heart failure (HF), but no data are available on the predictive role of irisin in patients with type 2 diabetes mellitus (T2DM) and different phenotypes of HF. The aim of the study was to investigate whether serum levels of irisin predict HF in T2DM patients. We prospectively included 183 participants with T2DM aged 41 to 62 years (30 non-HF patients and 153 HF patients) and 25 healthy volunteers in the study and evaluated clinical data, hemodynamics and biomarkers (N-terminal pro-brain natriuretic peptide (NT-proBNP) and irisin). Serum levels of irisin < 8.30 ng/mL were found to be a better indicator of HF with reduced ejection fraction (HFrEF) than irisin ≥ 8.30 ng/mL, but the predictive cut-off point for NT-proBNP remained the same as for HF with mildly reduced ejection fraction (HFmrEF). Serum levels of irisin < 10.4 ng/mL significantly improved the predictive ability of NT-proBNP for HF with preserved ejection fraction (HFpEF). In conclusion, we found that decreased serum levels of irisin significantly predicted HFpEF, rather than HFmrEF and HFrEF, in T2DM patients. This finding may open a new approach to HF risk stratification in T2DM patients.
Keywords
- Biomarkers, Diabetes Mellitus, Type 2, Fibronectins, Heart Failure/diagnosis, Humans, Phenotype, Stroke Volume, natriuretic peptides, heart failure with preserved ejection fraction, heart failure with mildly reduced ejection fraction, prediction, type 2 diabetes mellitus, irisin, heart failure with reduced ejection fraction
ASJC Scopus subject areas
Sustainable Development Goals
Cite this
- Standard
- Harvard
- Apa
- Vancouver
- BibTeX
- RIS
In: Cells, Vol. 11, No. 18, 2794, 07.09.2022.
Research output: Contribution to journal › Article › Research › peer review
}
TY - JOUR
T1 - Discriminative Value of Serum Irisin in Prediction of Heart Failure with Different Phenotypes among Patients with Type 2 Diabetes Mellitus
AU - Berezin, Alexander A
AU - Lichtenauer, Michael
AU - Boxhammer, Elke
AU - Stöhr, Eric
AU - Berezin, Alexander E
PY - 2022/9/7
Y1 - 2022/9/7
N2 - Recent studies have shown that circulating levels of irisin are prognostic factors in heart failure (HF), but no data are available on the predictive role of irisin in patients with type 2 diabetes mellitus (T2DM) and different phenotypes of HF. The aim of the study was to investigate whether serum levels of irisin predict HF in T2DM patients. We prospectively included 183 participants with T2DM aged 41 to 62 years (30 non-HF patients and 153 HF patients) and 25 healthy volunteers in the study and evaluated clinical data, hemodynamics and biomarkers (N-terminal pro-brain natriuretic peptide (NT-proBNP) and irisin). Serum levels of irisin < 8.30 ng/mL were found to be a better indicator of HF with reduced ejection fraction (HFrEF) than irisin ≥ 8.30 ng/mL, but the predictive cut-off point for NT-proBNP remained the same as for HF with mildly reduced ejection fraction (HFmrEF). Serum levels of irisin < 10.4 ng/mL significantly improved the predictive ability of NT-proBNP for HF with preserved ejection fraction (HFpEF). In conclusion, we found that decreased serum levels of irisin significantly predicted HFpEF, rather than HFmrEF and HFrEF, in T2DM patients. This finding may open a new approach to HF risk stratification in T2DM patients.
AB - Recent studies have shown that circulating levels of irisin are prognostic factors in heart failure (HF), but no data are available on the predictive role of irisin in patients with type 2 diabetes mellitus (T2DM) and different phenotypes of HF. The aim of the study was to investigate whether serum levels of irisin predict HF in T2DM patients. We prospectively included 183 participants with T2DM aged 41 to 62 years (30 non-HF patients and 153 HF patients) and 25 healthy volunteers in the study and evaluated clinical data, hemodynamics and biomarkers (N-terminal pro-brain natriuretic peptide (NT-proBNP) and irisin). Serum levels of irisin < 8.30 ng/mL were found to be a better indicator of HF with reduced ejection fraction (HFrEF) than irisin ≥ 8.30 ng/mL, but the predictive cut-off point for NT-proBNP remained the same as for HF with mildly reduced ejection fraction (HFmrEF). Serum levels of irisin < 10.4 ng/mL significantly improved the predictive ability of NT-proBNP for HF with preserved ejection fraction (HFpEF). In conclusion, we found that decreased serum levels of irisin significantly predicted HFpEF, rather than HFmrEF and HFrEF, in T2DM patients. This finding may open a new approach to HF risk stratification in T2DM patients.
KW - Biomarkers
KW - Diabetes Mellitus, Type 2
KW - Fibronectins
KW - Heart Failure/diagnosis
KW - Humans
KW - Phenotype
KW - Stroke Volume
KW - natriuretic peptides
KW - heart failure with preserved ejection fraction
KW - heart failure with mildly reduced ejection fraction
KW - prediction
KW - type 2 diabetes mellitus
KW - irisin
KW - heart failure with reduced ejection fraction
UR - http://www.scopus.com/inward/record.url?scp=85138392868&partnerID=8YFLogxK
U2 - 10.3390/cells11182794
DO - 10.3390/cells11182794
M3 - Article
C2 - 36139374
VL - 11
JO - Cells
JF - Cells
SN - 2073-4409
IS - 18
M1 - 2794
ER -